Purpose Bone metastasis from hepatocellular carcinoma (HCC) can present with soft tissue formation, resulting in oncologic emergency. Contrast-enhanced FDG PET/CT and bone scintigraphy were compared to evaluate characteristics of bone metastases with or without soft tissue formation from HCC. Methods Of 4,151 patients with HCC, 263 patients had bone metastases. Eighty-five patients with bone metastasis from HCC underwent contrast-enhanced FDG PET/CT. Fifty-four of the enrolled subjects had recent 99m Tc-HDP bone scintigraphy available for comparison. Metastatic bone lesions were identified with visual inspection on FDG PET/CT, and maximum standardized uptake value (SUV max ) was used for the quantitative analysis. Confirmation of bone metastasis was based on histopathology, combined imaging modalities, or serial follow-up studies. Results Forty-seven patients (55%) presented with soft tissue formation, while the remaining 38 patients presented without soft tissue formation. Frequent sites of bone metastases from HCC were the spine (39%), pelvis (19%), and rib cage (14%). The soft-tissue-formation group had more frequent bone pain (77 vs. 37%, p<0.0001), higher SUV max (6.02 vs. 3.52, p<0.007), and higher incidence of photon defect in bone scintigraphy (75 vs. 0%) compared to the non-soft-tissue-formation group. FDG PET/CT had higher detection rate for bone metastasis than bone scintigraphy both in lesion-based analysis (98 vs. 53%, p=0.0015) and in patient-based analysis (100 vs. 80%, p<0 .001). Conclusions Bone metastasis from HCC showed a high incidence of soft tissue formation requiring emergency treatment. Although the characteristic findings for soft tissue formation such as photon defect in bone scintigraphy are helpful in detection, overall detectability of bone metastasis is higher in FDG PET/CT. Contrast-enhanced PET/CT will be useful in finding and delineating softtissue-forming bone metastasis from HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common solid malignancies in the world, and its prevalence is higher in Asian countries [1] . HCC accounts for over 80% of all primary liver cancers, which rank fourth among cancer-related deaths worldwide [2] . The incidence of extrahepatic metastases from HCC was reported to be 37% with the following order of frequency: the lung, lymph nodes, and bone [3] . The extrahepatic metastases occur in advanced stages, and an accurate diagnosis of extraheptic metastases is of great value for determining the therapeutic modality at an early stage [4] .
Bone metastasis from HCC is not uncommon, and the incidence has been increasing [5, 6] . A recent study reported that patients with isolated bone metastasis showed longer survival than those with metastases in bone and other sites [7] . Meanwhile, bone metastases-associated expansile soft tissue mass and bony destruction can cause clinical emergencies such as severe pain, spinal cord compression, and paralysis. Therefore, immediate operation or radiation therapy should be considered in bone metastasis with soft tissue formation [8] [9] [10] . However, the clinical importance of bone metastasis from HCCoriginated soft tissue components has been underestimated due to the low incidence in Western countries. 99m Tc-MDP or HDP bone scintigraphy (BS) has been widely used to detect bone metastasis in most malignancies. Due to the osteolytic nature of bone metastasis from HCC, the detectability of BS has been reported to be lower compared with cancers with osteoblastic metastasis [11] [12] [13] . Bony destruction resulting from osteolytic metastasis can present with photon defects in BS [14] [15] [16] , but the correlation with 18 F-fluoro-2-deoxy-D-glucose (FDG) PET/ CT has not been explored.
FDG PET/CT has been known to be less suitable for primary HCC due to limited detectability [17] . However, several studies reported that PET or PET/CT is useful for detection of extrahepatic metastases from HCC [18] [19] [20] [21] . Moreover, PET/CT showed higher sensitivity for the detection of bone metastasis than other extrahepatic metastases from HCC [22] . The aim of the present study is to evaluate the feasibility of FDG PET/CT for assessing bone metastasis from HCC and to describe imaging characteristics of bone metastases from HCC according to the presence of soft tissue formation.
Materials and Methods

Patients
We reviewed 4,151 patients diagnosed with HCC between January 2005 and December 2010. Of the 263 patients confirmed to have bone metastasis, 103 patients underwent contrast-enhanced PET/CT for the evaluation of suspicious bone metastasis and/or other extrahepatic metastasis. In our institute, contrast-enhanced PET/CT is routinely performed in most patients with HCC when extrahepatic metastases are suspected based on laboratory examinations, clinical symptoms, CT, and other imaging modalities. Eighteen patients were excluded from the study for the following reasons: 13 patients had diffuse bone metastases; 2 patients had double primary; and 3 patients were not confirmed as having bone metastasis. Ultimately, a total of 85 patients were included in this study.
Contrast-Enhanced FDG PET/CT
All patients were instructed to fast for 8 h except for glucose-free oral hydration before the PET examination, and the blood glucose concentration was measured and confirmed to be less than 140 mg/dL. Intravenous injections of 5.5 MBq of 18 F-FDG per kilogram of body weight were administered. All patients were kept lying comfortably during the 60 min uptake period and voided before being supinely positioned on the scanner table. Integrated FDG PET/CT scanning was performed using a combined PET/ CT scanner (Discovery STE; GE Healthcare, Milwaukee, WI). Sixty minutes after the 18 F-FDG injection, the first unenhanced CT scan with eight-slice scanner was performed from the vertex of the skull through the mid-thigh using the following parameters: 120 kVp; 30 mA; 0.8 s rotation time; 3.75 mm helical thickness; 27 mm per rotation (speed); 2.5 mm scan reconstruction, with a reconstruction index of 1.25 mm; 15.7 cm field of view; and a 512×512 matrix. A PET scan was then acquired from the level of the ear through the mid-thigh in threedimensional mode at 2.5 min per bed position. The PET unit had an axial field of view of 50 cm and a spatial resolution of 4.29 mm in full width of half maximum at 1 cm from the center. PET data were reconstructed iteratively using an ordered-subset expectation maximization algorithm. After finishing PET scans, 2 ml/s of contrast medium (Omnipaque 300, GE Healthcare) was injected, and a contrast-enhanced CT scan of the same imaging field was obtained immediately at 120 kVp and 230 mA, with a helical thickness of 3.75 mm, 60 s. The reconstructed CT, PET, and fused PET/CT images were displayed in axial, sagittal, and coronal planes.
Contrast-enhanced PET/CT was interpreted by two experienced nuclear medicine physicians (who had 3-4 years of experience with contrast-enhanced PET/CT) without knowledge of the patient's clinical history. A bone lesion on PET/CT was regarded as bone metastasis if two nuclear medicine physicians agreed that there was abnormally increased FDG uptake compared with background bone marrow and osteolytic/osteoblastic change with/ without bony destruction on bone window setting CT.
A region of interest (ROI) was placed over all suspected bone lesions to measure maximum intensity in each lesion for semi-quantitative analysis. The standardized uptake value (SUV) was calculated by using the following formula: radioactivity concentration in the region of interest (Bq/ml)/(injected dose of FDG/body weight in grams). The value of SUV max of metastatic bone lesion was not used for the visual interpretation.
On contrast-enhanced CT as part of PET/CT, the presence of the soft-tissue component was evaluated using CT attenuation values (Hounsfield units). Soft tissue formation was determined by reviewing nonenhanced and contrast-enhanced CT. Bone destructive lesion with soft tissue density that was well-enhanced by contrast dye was considered soft tissue formation (Fig. 1 ).
Tc-99m HDP Bone Scintigraphy
Bone scintigraphy was performed using a dual-head gamma camera (ADAC Dual genesys, ADAC Laboratories, Milpitas, CA) equipped with general-purpose collimators. Anterior and posterior whole-body images were acquired approximately 3 h after intravenous administration of 925 MBq 99m Tc-hydroxymethane diphosphonate (HDP). Additional static planar images were acquired at the discretion of the attending nuclear physician. Single photon emission computed tomography was not performed routinely.
Bone scintigraphy was interpreted by two experienced nuclear medicine physicians (who had 3-4 years of experience with bone scintigraphy) without knowledge of the patient's clinical history. A bone lesion on bone scintigraphy was considered as significant if it showed abnormal uptake excluding lesions interpreted as arthritis, osteophytes, or benign compression fracture. A lesion with a central cold defect was considered to be a malignant lesion [23, 24] .
Determination of Bone Metastasis
Confirmation of bone metastasis by biopsy was available in 18 patients. All other lesions not confirmed by biopsy were considered to be true-positive findings if at least one of the following criteria was satisfied: (1) serial PET/CT scans (obtained at 3-6 month follow-up; 11 patients) showing increasing lesion size and/or FDG accumulation, (2) positive findings of bone metastasis on concomitant or follow-up MR finding (23 patients), (3) serial CT findings of osteolytic and/or destructive changes (15 patients), (4) osteolytic/osteoblastic lesions with abnormally increased FDG uptake and/or expansile or erosive cortical changes present on contrast-enhanced PET/CT (6 patients), (5) concomitant or follow-up bone scintigraphy findings with bone involvement (22 patients) [7] . Ten patients were confirmed based on more than two criteria.
Statistical Analysis
All data were analyzed using statistical software (Medcalc Software, Mariakerke, Belgium). The mean age of men and women was compared using the independent-sample t test. The χ 2 test was used to compare the patients' background characteristics and symptoms. Survival rate was evaluated by the Kaplan-Meier method, and the log-rank test was used to compare survival rates. An alternative-free response receiver operating characteristic (ROC) curve was analyzed to find the cut-off value of bone metastasis with soft-tissue component. P<0.05 was considered statistically significant.
Results
Patient Characteristics
A total of 85 patients were enrolled in the present study (70 male and 15 female patients, mean age 58 years). Among the 85 patients, 47 were diagnosed as having soft tissue formation, and 38 were diagnosed as having no soft tissue formation. Demographic characteristics of each group are displayed in Table 1 differentiation, combined extrahepatic metastasis, and isolated bone metastasis were compared between the softtissue-forming group and non-forming group, but no significant difference was found. The soft-tissue-forming group showed higher prevalence of bone pain than the non-forming group (37 vs. 77%, P<0.0001).
Bone Metastasis Site Distribution
A total of 211 bone metastatic sites were detected. Of 211 sites, 81 lesions (38%) were classified as soft-tissueforming metastasis. The regional distribution of bone metastatic sites is listed in Table 2 . The frequent sites of bone metastasis from HCC were the spine (n=100, 48%) , followed by pelvis (n=40, 19%) and rib cage (n=30, 14%). There was no significant difference in the affected sites between the soft-tissue-forming group and the non-forming group, except for the high frequency of soft-tissue-forming metastasis in the rib cage (Fig. 2) .
Detection Rate by FDG PET/CT and 99m
Tc-HDP Bone Scintigraphy
Comparison of detection rate between FDG PET/CT and bone scintigraphy was performed in 54 patients who underwent both procedures (Table 3) . On a lesion-based analysis, the detection rate of FDG PET/CT was 98% (134/ (detection rate, 100 vs. 80%), but the difference was significant only in the non-soft-tissue-forming group.
Diagnostic Value of Mean SUV max SUV max was significantly higher in the soft-tissue-forming group than the non-forming group (Fig. 3, 6 .02±3.58 vs. 3.52±2.37). ROC curve revealed the cut-off value of 3.7 SUV max to predict a soft-tissue component but did not reach statistical significance (area under curve 0.723, sensitivity 66.7%, and specificity 68.5%).
Photon Defect on 99m Tc-HDP Bone Scintigraphy Typical 99m Tc-HDP bone scintigraphic finding suggestive of soft tissue formation was defined as photon defect with marginal increased uptake (Fig. 4) . Of the 28 soft tissue lesions, typical findings were detected in 21 lesions on bone scintigraphy (75%), and the most frequent sites were rib cage and spine (Tables 4, 5).
Discussion
The incidence of HCC is increasing in countries where hepatitis B or C virus is endemic [6] . The present study enrolled a relatively large number of patients with bone metastases from HCC and showed better detectability of FDG PET/CT than bone scintigraphy. In addition, we focused on the high prevalence of soft-tissue-forming metastasis in HCC, which is consistent with previous reports [8, 10, 25] .
The incidence of bone metastasis in HCC has been reported to be 6-10% [7, 26] . The relatively low frequency of bone metastasis from HCC is thought to be related to the fact that most bone metastatic lesions from HCC are osteolytic metastases, which could be missed with conventional bone scintigraphy [27] . However, because FDG PET evaluates the tumor cells in bone metastatic lesions rather than osteoblastic reaction, it is expected to be more sensitive than bone scintigraphy. The incidence of bone metastasis measured by FDG PET in our study was 5.5%, which is consistent with the incidences in the literature. However, one recent study reported that the frequency of bone metastasis from HCC was 19% [7] , therefore more studies enrolling larger study groups will be needed to assess the prevalence of bone metastasis from HCC.
Bone metastasis from HCC has the unique characteristic of a high incidence of soft tissue formation. Fukutomi et al. reported that 24 out of 29 lesions (83%) showed osteolysis with expansile soft tissue formation [5] . Kim et al. reported 54% of HCC cases showed soft tissue formation [28] , and our study showed 55% of HCC cases showed soft tissue formation on patient-based analysis. Despite the relatively low incidence of bone metastasis, soft tissue formation requiring emergency treatment is frequently observed in HCC, and imaging studies to assess soft tissue formation can be of great clinical importance. Although patients with bone metastasis had markedly elevated AFP, the levels of AFP were not significantly different between the softtissue-forming group and the non-forming group in this study. Clinically, the soft-tissue-forming group suffered more bone pain and had higher SUV levels than the nonforming group. According to the results of this study, it is recommended that lesions with symptomatic pain and high SUV level on FDG PET should be carefully examined to determine the presence of soft tissue formation.
99m Tc-MDP or HDP bone scintigraphy has been widely used as a diagnostic modality for screening patients with suspicious metastatic bone disease from various malignancies for decades. However, osteolytic lesions may not be detected on bone scintigraphy, and it has been known to be the pitfall of bone scintigraphy [25, 29] . In this study, all bone metastases from HCC were osteolytic, and the detection rate of bone scintigraphy was low. As is wellknown, the detection rate of bone scintigraphy for HCC is much lower than those of breast cancer [11] and lung cancer [30] . However, the characteristic findings of photon defects in soft-tissue-forming lesions can be helpful when Outside value* indicates a value that is larger than the upper quartile plus 1.5 times the interquartile range evaluated for osteolytic metastasis in bone scintigraphy. In this study, photon defect was frequently found on softtissue-forming lesions with an incidence of 75%. Photon defect is a well known finding on bone scintigraphy that can be observed in osteolytic metastasis [14] [15] [16] , and we demonstrated that photon defect on bone scintigraphy in HCC is directly related to a high prevalence of soft tissue formation. Overall, the detection rate of FDG PET was superior to bone scintigraphy in the present study. FDG PET has limitations for the diagnosis of primary HCC because of high levels of glucose-6-phosphatase in HCCs, especially in well-differentiated tumors [31] [32] [33] . Only a few studies have assessed the diagnostic accuracy of FDG PET in bone metastasis from HCC [34] . Although this study compared detection rates of FDG PET and whole-body bone scintigraphy in selected patients with known bone metastasis, the overall diagnostic accuracy is expected to be higher in FDG PET than bone scintigraphy. Three lesions missed on FDG PET/CT were all pure osteolytic without increased FDG uptake, probably due to recent chemotherapy.
We found in our study that 47 out of 85 (55%) of our patients had isolated bone metastasis, which is consistent with a previous study by Ho et al. They reported that isolated bone metastasis in HCC might not be as uncommon as previously believed, and more common than metastasis to other regions [7] . As is well known, whole body screening with FDG PET or bone scintigraphy is crucial in screening for bone metastasis, and these imaging studies should be considered even in patients without other soft tissue metastasis.
In the present study, six patients with soft tissue formation underwent emergency operation due to impending cord compression and paralysis (data not presented). Non-contrast CT as part of PET/CT can find the destruction of cortex but is limited in delineating the expanding pattern escaping from bone. FDG uptake on soft tissue lesion detected on nonenhanced CT might be the clue to softtissue formation. Furthermore, contrast-enhanced CT is routinely performed in most oncologic PET/CT studies in our institute and was performed in all the patients enrolled in this study. Contrast-enhanced CT was especially useful for the evaluation of the extension to the nerve and adjacent tissue, which could be a guideline for further studies including MRI and for the treatment plan.
There were several limitations in this study. Not all of the lesions were confirmed by histopathology. However, this is a well-known limitation of most studies assessing bone metastases, and a clinical decision can be made without pathology confirmation when typical imaging findings are present [3] . Second, the study group comprised a heterogeneous group of patients for staging and follow-up. Fortyfour of them had previous treatment history of radiotherapy, chemotherapy, liver resection, transcatheter arterial infusion chemotherapy, and/or radiofrequency ablation therapy. This can be a limitation of evaluation of bone metastasis. Third, only subjects who underwent FDG PET/CT were selected from a total of 263 patients diagnosed with bone metastasis from HCC. Possible selection bias cannot be excluded.
In conclusion, the incidence of bone metastases from HCC is not uncommon, and high incidence of soft tissue formation has unique imaging and clinical characteristics. Although FDG PET was superior to bone scintigraphy in the detection of bone metastasis, bone scintigraphy could be used for screening and for identifying soft-tissueforming metastasis. Detection of expanding soft tissue lesions on nonenhanced CT, high FDG uptake on areas of soft tissue density, and photon defect on bone scintigraphy were considered as possible indicators of soft-tissueforming bone metastasis, and enhanced CT for identification of enhancing mass lesions could aid in diagnosis.
